These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 30316729)

  • 41. Monitoring Substantia Nigra Degeneration Using Free Water Imaging across Prodromal and Clinical Parkinson's Disease.
    Zhou G; Ren J; Rong D; Zhou H; Ning H; Wang H; Pan C; Wang Y; Zhang R; Guo Z; Huang P; Liu W
    Mov Disord; 2023 May; 38(5):774-782. PubMed ID: 36947674
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Magnetic resonance correlation of iron content with neuromelanin in the substantia nigra of early-stage Parkinson's disease.
    Reimão S; Ferreira S; Nunes RG; Pita Lobo P; Neutel D; Abreu D; Gonçalves N; Campos J; Ferreira JJ
    Eur J Neurol; 2016 Feb; 23(2):368-74. PubMed ID: 26518135
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Substantia nigra hyperechogenicity does not correlate with motor features in Parkinson's disease.
    Jesus-Ribeiro J; Sargento-Freitas J; Sousa M; Silva F; Freire A; Januário C
    J Neurol Sci; 2016 May; 364():9-11. PubMed ID: 27084206
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Substantia nigra fractional anisotropy is not a diagnostic biomarker of Parkinson's disease: A diagnostic performance study and meta-analysis.
    Hirata FCC; Sato JR; Vieira G; Lucato LT; Leite CC; Bor-Seng-Shu E; Pastorello BF; Otaduy MCG; Chaim KT; Campanholo KR; Novaes NP; Melo LM; Gonçalves MR; do Nascimento FBP; Teixeira MJ; Barbosa ER; Amaro E; Cardoso EF
    Eur Radiol; 2017 Jun; 27(6):2640-2648. PubMed ID: 27709279
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Is R2* a new MRI biomarker for the progression of Parkinson's disease? A longitudinal follow-up.
    Ulla M; Bonny JM; Ouchchane L; Rieu I; Claise B; Durif F
    PLoS One; 2013; 8(3):e57904. PubMed ID: 23469252
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Magnetic Resonance Imaging Features of the Nigrostriatal System: Biomarkers of Parkinson's Disease Stages?
    Hopes L; Grolez G; Moreau C; Lopes R; Ryckewaert G; Carrière N; Auger F; Laloux C; Petrault M; Devedjian JC; Bordet R; Defebvre L; Jissendi P; Delmaire C; Devos D
    PLoS One; 2016; 11(4):e0147947. PubMed ID: 27035571
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Plasma homocysteine level and its relationship to clinical profile in Parkinson's disease patients at the Lagos University Teaching Hospital.
    Ojo OO; Oladipo OO; Ojini FI; Sanya EO; Danesi MA; Okubadejo NU
    West Afr J Med; 2011; 30(5):319-24. PubMed ID: 22752818
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Enlarged hyperechogenic substantia nigra as a risk marker for Parkinson's disease.
    Berg D; Behnke S; Seppi K; Godau J; Lerche S; Mahlknecht P; Liepelt-Scarfone I; Pausch C; Schneider N; Gaenslen A; Brockmann K; Srulijes K; Huber H; Wurster I; Stockner H; Kiechl S; Willeit J; Gasperi A; Fassbender K; Gasser T; Poewe W
    Mov Disord; 2013 Feb; 28(2):216-9. PubMed ID: 23115051
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Diagnostic value of combined assessment of olfaction and sustantia nigra hyperechogenicity for Parkinson's disease.
    López Hernández N; García Escrivá A; Shalabi Benavent M
    Neurologia; 2015 Oct; 30(8):496-501. PubMed ID: 24839905
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Longitudinal changes in free-water within the substantia nigra of Parkinson's disease.
    Ofori E; Pasternak O; Planetta PJ; Li H; Burciu RG; Snyder AF; Lai S; Okun MS; Vaillancourt DE
    Brain; 2015 Aug; 138(Pt 8):2322-31. PubMed ID: 25981960
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Substantia nigra neuromelanin-MR imaging differentiates essential tremor from Parkinson's disease.
    Reimão S; Pita Lobo P; Neutel D; Guedes LC; Coelho M; Rosa MM; Azevedo P; Ferreira J; Abreu D; Gonçalves N; Nunes RG; Campos J; Ferreira JJ
    Mov Disord; 2015 Jun; 30(7):953-9. PubMed ID: 25758364
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Quantitative Analysis Versus Visual Assessment of Neuromelanin MR Imaging for the Diagnosis of Parkinson's disease.
    Reimão S; Pita Lobo P; Neutel D; Guedes LC; Coelho M; Rosa MM; Ferreira J; Abreu D; Gonçalves N; Morgado C; Nunes RG; Campos J; Ferreira JJ
    J Parkinsons Dis; 2015; 5(3):561-7. PubMed ID: 26406136
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Substantia nigra fractional anisotropy changes confirm the PD at-risk status of patients with idiopathic smell loss.
    Haehner A; Schöpf V; Loureiro A; Linn J; Reichmann H; Hummel T; Kitzler HH
    Parkinsonism Relat Disord; 2018 May; 50():113-116. PubMed ID: 29477459
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Microstructure of Brain Nuclei in Early Parkinson's Disease: Longitudinal Diffusion Kurtosis Imaging.
    Welton T; Hartono S; Shih YC; Lee W; Chai PH; Chong SL; Ng SYE; Chia NSY; Choi X; Heng DL; Tan EK; Tan LCS; Chan LL
    J Parkinsons Dis; 2023; 13(2):233-242. PubMed ID: 36744346
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Magnetic Resonance Imaging Biomarkers to Assess Substantia Nigra Damage in Idiopathic Rapid Eye Movement Sleep Behavior Disorder.
    Pyatigorskaya N; Gaurav R; Arnaldi D; Leu-Semenescu S; Yahia-Cherif L; Valabregue R; Vidailhet M; Arnulf I; Lehéricy S
    Sleep; 2017 Nov; 40(11):. PubMed ID: 28958075
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Seven-Tesla magnetic resonance images of the substantia nigra in Parkinson disease.
    Kwon DH; Kim JM; Oh SH; Jeong HJ; Park SY; Oh ES; Chi JG; Kim YB; Jeon BS; Cho ZH
    Ann Neurol; 2012 Feb; 71(2):267-77. PubMed ID: 22367998
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Correlation of dopaminergic terminal dysfunction and microstructural abnormalities of the basal ganglia and the olfactory tract in Parkinson's disease.
    Scherfler C; Esterhammer R; Nocker M; Mahlknecht P; Stockner H; Warwitz B; Spielberger S; Pinter B; Donnemiller E; Decristoforo C; Virgolini I; Schocke M; Poewe W; Seppi K
    Brain; 2013 Oct; 136(Pt 10):3028-37. PubMed ID: 24014521
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Transcranial imaging of substantia nigra hyperechogenicity in a Taiwanese cohort of Parkinson's disease.
    Huang YW; Jeng JS; Tsai CF; Chen LL; Wu RM
    Mov Disord; 2007 Mar; 22(4):550-5. PubMed ID: 17260344
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Iron deposition in Parkinson's disease by quantitative susceptibility mapping.
    Chen Q; Chen Y; Zhang Y; Wang F; Yu H; Zhang C; Jiang Z; Luo W
    BMC Neurosci; 2019 May; 20(1):23. PubMed ID: 31117957
    [TBL] [Abstract][Full Text] [Related]  

  • 60. 7 Tesla magnetic resonance imaging: a closer look at substantia nigra anatomy in Parkinson's disease.
    Lehéricy S; Bardinet E; Poupon C; Vidailhet M; François C
    Mov Disord; 2014 Nov; 29(13):1574-81. PubMed ID: 25308960
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.